Clinical observation on combined treatment of chronic nephritis proteinuria,a report of 22 cases
10.3760/cma.j.issn.1008-6706.2016.22.024
- VernacularTitle:综合治疗慢性肾炎蛋白尿22例临床观察
- Author:
Chao WANG
- Publication Type:Journal Article
- Keywords:
Proteinuria;
Nephrosis,lipoid;
Zhengqingfengtongning release tablets;
Lumbrokinase enteric -coated capsules;
Losartan potassium tablets
- From:
Chinese Journal of Primary Medicine and Pharmacy
2016;23(22):3452-3455
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the curative effect of Zhengqingfengtongning release tablets and lumbroki-nase enteric -coated capsules and losartan potassium tablets joint for the treatment of chronic nephritis proteinuria, and explore its mechanism.Methods 42 patients with chronic nephritis were randomly divided into two groups. 20 cases in the control group were given losartan potassium tablets,50mg,1 ~2 times a day.22 cases in the treatment group received Zhengqingfengtongning release tablets 120mg,2 times a day,lumbrokinase enteric -coated capsules 600 000u,3 times a day on the basis of the control group.The 24h urine protein,liver and kidney function before and after the treatment were observed.Results 20 days after treatment,24h urinary protein in the treatment group decreased 57.08%,which in the control group decreased 41.59%,the difference was statistically significant (t =2.39,P <0.05).30 days after treatment,24h urinary protein in the treatment group decreased 81.28%,which in the control group decreased 52.34%,the difference was statistically significant (t =3.65,P <0.01 ).Renal function change had no significant difference between the two groups.Conclusion Zhengqingfengtongning release tablets and lumbrokinase enteric -coated capsules combined with losartan potassium tablets in the treatment of chronic nephritis proteinuria work fast,and has good curative effect,less side effects,and is worth to recommend.
